MALT1 and glioblastoma: In GBM, MALT1 inhibition, such as with MI-2, leads to reduced tumor cell proliferation, migration, and invasion, induces G1 cell cycle arrest, and enhances immune reactivity in the tumor microenvironment, making it a promising therapeutic target [47].